Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability

Published: March 2014
No. of Pages: 66
   

GBI Research, the leading business intelligence provider, has released its latest research, ""Epilepsy Therapeutics in Asia Pacific Markets to 2019 Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability"", which provides in-depth analysis of epilepsy market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The value of the epilepsy market in the APAC region amounted to an estimated $1.1 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 4.7% to reach $1.5 billion by 2019. The key drivers for growth in the APAC market include: high prevalence in China and India, increased market penetration due to improved market access in China and the expected approvals of drugs with novel mechanisms of action which could expand the therapeutic scope. Conversely, the growth of the market in APAC region could face the restricting influence of prescribing patterns that give preference to older generation drugs and also due to generic competition as a result of key patent expiries.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in anti-epileptics in the four APAC markets of Australia, China, India and Japan. The report includes

  • A brief introduction to epilepsy, including disease pathogenesis, risk factors, diagnosis and treatment options
  • In-depth analysis of major marketed products covering product performance, product life-cycle and a heat map depicting comparative analysis of safety and efficacy parameters
  • A comprehensive review of the epilepsy pipeline which includes individual analysis of promising late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of Phase distribution, molecule type and molecular target.
  • Additional clinical trial analysis by Phase, trial size, trial duration and program failure rate for each molecule type and mechanism of action
  • Multi-scenario forecasts of the epilepsy market from 2012 to 2019 in the four APAC regions
  • In-depth analysis of licensing and co-development agreements and an overview of key agreements that could impact growth trends
  • Key drivers and restraints that have had and are expected to have a significant impact upon the market

Reasons to buy

  • The report will enhance your decision-making capability by allowing you to
  • Align your product portfolio to markets with high growth potential
  • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
  • Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the anti-epileptic drugs market
  • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Introduction 9
2.1 Disease Overview 9
2.2 Epidemiology 9
2.3 Symptoms 10
2.4 Etiology 11
2.5 Pathophysiology 11
2.6 Co-morbidities/Complications 12
2.7 Diagnosis 12
2.8 Prognosis 12
2.9 Treatment Efficacy 12
2.10 Treatment Options 13
2.10.1 Ion Channel Modulators 13
2.10.2 GABA-ergic Facilitation 13
2.10.3 Excitatory Amino Acid Inhibitors 13
2.10.4 Synaptic Modulators 13
2.11 Non-pharmacological Management 14
2.11.1 Lobectomy and Lesionectomy 14
2.11.2 Ketogenic Diet and Modified Atkins Diet 14
2.11.3 Vagus Nerve Stimulation 14

3 Epilepsy Therapeutic Landscape 15
3.1 Overview 15
3.2 Lyrica (pregabalin) 15
3.3 Lamictal (lamotrigine) 16
3.4 Keppra (levetiracetam) 17
3.5 Zonegran (zonisamide) 19
3.6 Vimpat (lacosamide) 20
3.7 Aptiom/Zebinix (eslicarbazepine acetate) 22
3.8 Fycompa (perampanel) 22
3.9 Trobalt/Potiga (ezogabine/retigabine) 23
3.10 Banzel/Inovelon (rufinamide) 24
3.11 Comparative Efficacy and Safety of Marketed Products 24

4 Pipeline for Epilepsy Therapeutics 27
4.1 Overall Pipeline 27
4.2 Pipeline by Mechanism of Action 29
4.3 Clinical Trials 30
4.3.1 Failure Rate 30
4.3.2 Patient Enrolment and Clinical Trial Size 32
4.3.3 Clinical Trial Duration 33
4.4 Promising Pipeline Candidates 34
4.4.1 Brivaracetam – UCB 34
4.4.2 Ganaxolone – Marinus Pharmaceuticals 34

5 Epilepsy Therapeutics Market Forecast to 2019 35
5.1 Geographical Markets 35
5.1.1 Key Asia-Pacific Markets 35
5.1.2 China 37
5.1.3 India 39
5.1.4 Japan 41
5.1.5 Australia 43
5.2 Drivers and Barriers 45
5.2.1 Drivers 45
5.2.2 Barriers 45

6 Deals and Strategic Consolidations 46
6.1 Deals Analysis 46
6.2 Research and Development Co-development Agreements 48
6.3 Research and Development Licensing Agreements 49

7 Appendix 51
7.1 Abbreviations 51
7.2 References 52
7.3 References for Heat Maps 56
7.4 Pipeline Products by Phase 57
7.4.1 Discovery 57
7.4.2 Preclinical 58
7.4.3 IND-filed and Phase 0 59
7.4.4 Phase I 59
7.4.5 Phase II 60
7.4.6 Phase III 61
7.4.7 Pre-registration 61
7.5 Market Forecasting Data Tables to 2019 62
7.5.1 Asia-Pacific 62
7.5.2 China 62
7.5.3 India 62
7.5.4 Japan 63
7.5.5 Australia 63
7.6 Research Methodology 63
7.6.1 Coverage 63
7.6.2 Secondary Research 64
7.6.3 Primary Research 64
7.6.4 Therapeutic Landscape 64
7.6.5 Geographical Landscape 67
7.6.6 Pipeline Analysis 67
7.7 Expert Panel Validation 67
7.8 Contact Us 67
7.9 Disclaimer 67

List of Tables

Table 1: Epilepsy Therapeutics, Global, Types of Seizures, 2013 9
Table 2: Epilepsy Therapeutics, Heat Maps for Efficacy and Safety of Marketed Products, References 56
Table 3: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Discovery), 2013 57
Table 4: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Preclinical), 2013 58
Table 5: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (IND/CTA-filed), 2013 59
Table 6: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase I), 2013 59
Table 7: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase II), 2013 60
Table 8: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase III), 2013 61
Table 9: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Pre-registration), 2013 61
Table 10: Epilepsy Therapeutics, Asia-Pacific, Market Forecast, 2012–2019 62
Table 11: Epilepsy Therapeutics, China, Market Forecast, 2012–2019 62
Table 12: Epilepsy Therapeutics, India, Market Forecast, 2012–2019 62
Table 13: Epilepsy Therapeutics, Japan, Market Forecast, 2012–2019 63
Table 14: Epilepsy Therapeutics, Australia, Market Forecast, 2012–2019 63

List of Figures

Figure 1: Epilepsy Therapeutics, Epidemiology, Asia-Pacific, 2012 10
Figure 2: Epilepsy Therapeutics, Lyrica, Global, Revenue ($bn), 2013 16
Figure 3: Epilepsy Therapeutics, Lamictal, Global, Revenue ($m), 2009–2013 17
Figure 4: Epilepsy Therapeutics, Keppra, Global, Revenue ($bn), 2009–2013 18
Figure 5: Epilepsy Therapeutics, Zonegran, Global, Revenue ($m), 2009–2013 19
Figure 6: Epilepsy Therapeutics, Vimpat, Global, Revenue ($m), 2009–2013 21
Figure 7: Epilepsy Therapeutics, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2013 25
Figure 8: Epilepsy Therapeutics, Global, Overall Pipeline Analysis, 2013 28
Figure 9: Epilepsy Therapeutics, Global, Pipeline Analysis, by Mechanism of Action, 2013 29
Figure 10: Epilepsy Therapeutics, Global, Clinical Trial Failure Rate, 2013 31
Figure 11: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Size, 2013 32
Figure 12: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Duration, 2013 33
Figure 13: Epilepsy Therapeutics, Asia-Pacific, Market Size, 2012–2019 36
Figure 14: Epilepsy Therapeutics, China, Market Size, 2012–2019 38
Figure 15: Epilepsy Therapeutics, India, Market Size, 2012–2019 40
Figure 16: Epilepsy Therapeutics, Japan, Market Size, 2012–2019 42
Figure 17: Epilepsy Therapeutics, Australia, Market Size, 2012–2019 44
Figure 18: Epilepsy Therapeutics, Deals by Region, Value and Year, 2006–2013 46
Figure 19: Epilepsy Therapeutics, Deals by Molecule Type and Mechanism of Action, 2006–2013 47
Figure 20: Epilepsy Therapeutics, Co-development Deals, Territory, 2006–2013 48
Figure 21: Epilepsy Therapeutics, Licensing Deals, by Territory, 2006–2013 49
Figure 22: GBI Research Market Forecasting Model 66

Published By: GBI Research
Product Code: GBI Research1468


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100